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Abstract
Prostaglandin E2 (PGE2) has been reported to modulate angiogenesis, the process of new blood vessel formation, by
promoting proliferation, migration and tube formation of endothelial cells. Endothelial progenitor cells are known as a
subset of circulating bone marrow mononuclear cells that have the capacity to differentiate into endothelial cells. However,
the mechanism underlying the stimulatory effects of PGE2 and its specific receptors on bone marrow-derived cells (BMCs) in
angiogenesis has not been fully characterized. Treatment with PGE2 significantly increased the differentiation and migration
of BMCs. Also, the markers of differentiation to endothelial cells, CD31 and von Willebrand factor, and the genes associated
with migration, matrix metalloproteinases 2 and 9, were significantly upregulated. This upregulation was abolished by
dominant-negative AMP-activated protein kinase (AMPK) and AMPK inhibitor but not protein kinase, a inhibitor. As a
functional consequence of differentiation and migration, the tube formation of BMCs was reinforced. Along with altered
BMCs functions, phosphorylation and activation of AMPK and endothelial nitric oxide synthase, the target of activated
AMPK, were both increased which could be blocked by EP4 blocking peptide and simulated by the agonist of EP4 but not
EP1, EP2 or EP3. The pro-angiogenic role of PGE2 could be repressed by EP4 blocking peptide and retarded in EP4
+/2 mice.
Therefore, by promoting the differentiation and migration of BMCs, PGE2 reinforced their neovascularization by binding to
the receptor of EP4 in an AMPK-dependent manner. PGE2 may have clinical value in ischemic heart disease.
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Introduction
Angiogenesis is a process of new blood vessel formation from the
existing vascular bed. Numerous studies have demonstrated that a
population of cells mobilized from bone marrow and circulating in
peripheral blood, participate in postnatal neovascularizaton [1,2].
Both animal and clinical studies have shown that circulating bone-
marrow derived cells (BMCs) are mobilized endogenously in
response to tissue ischemia and thereby augment neovascularization
during ischemia [3], tumor vasculature [4], wound healing [5] and
inflammation [5]. These cells home to vascular injury sites, adapt to
the endothelial phenotype, and contribute to angiogenesis, they was
named as endothelial progenitor cells (EPCs) [1,2]. Key determining
factors of these cells are adhesion at the site of injury and
differentiation into vascular endothelial cells (ECs). Although EPCs
have clinical implications for therapeutic vasculogenesis, the
identification of the involved cell populations and the mechanism
bywhichtheyparticipateinvascularrepairremainlargelyunknown.
Many growth factors, cytokines and chemokines are reported to be
involved in the process [3,6]. However, there are still no specific
markers for EPCs and assessment of cell purity, and results from
clinical trials remain controversial [5]. Even a proteomics-led
approach in early outgrowth EPCs raised the awareness that
markers used to define their endothelial potential might arise from
an uptake of platelet proteins [5]. Recently, Asahara’s group
consistently reported that mouse CD34(+) cells may represent a
functional EPC population in bone marrow [5]. In this study, the
term of BMCs was used to represent this group of cells.
Prostaglandin E2 (PGE2) is widely recognized as a mediator of
inflammation, capable of recruiting proinflammatory cells and
causing pain. PGE2 is also known to promote tumorigenesis
because of its causal association with tumor growth and its ability
to activate angiogenesis. Thus, PGE2 may contribute to the
mobilization of BMCs and promote neovascular formation [3,6].
PGE2 exerts its cellular effects by binding to 4 distinct
transmembrane-specific G-protein–coupled receptors, namely EP
1–4. EP1 mediates PGE2-induced intracellular calcium mobiliza-
tion. EP3 downregulates adenylate cyclase via Gi, thereby
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stimulate adenylate cyclase, thus resulting in increased intracellu-
lar cAMP formation. As well, EP4 but not EP2 couples to
phosphatidylinositol 3-kinase probably via Gi. Apparently, differ-
ent receptors mediate the diversified function of PGE2 in different
cell types. The role of different EP receptors in the differentiation
of BMCs is still elusive.
AMP-activated protein kinase (AMPK), a heteroteimeric
serine/threonine protein kinase, which is activated in many cell
types by increased intracellular concentrations of AMP, plays an
important role in angiogenesis when activated by vascular
endothelial growth factor (VEGF) [7,8,9], basic fibroblast growth
factor [10], adiponectin [11,12] and hypoxia [9]. We previously
reported that activation of AMPK and the consequent activation
of endothelial nitric oxide synthase (eNOS) play a pivotal role in
the differentiation of human EPCs [13].
Because of the important role of PGE2 as a mediator in the
inflammatory response and in angiogenesis, we tested the
hypothesis that PGE2 may also be a stimulator of the
differentiation of BMCs into mature ECs. Further, we studied
the mechanism of the beneficial effects of PGE2-mediated BMC
differentiation in vascular repair. Through promoting the
differentiation and migration of BMCs, PGE2 reinforced their
neovascularization by binding to the EP4 receptor in an AMPK-
dependent pathway.
Materials and Methods
Reagents
PGE2; the blocking peptides for EP1, EP2, EP3, EP4; and the
agonists for EP2 (Butaprost), EP3 (Sulprostone), and EP4 (PGE1
Alcohol) were from Cayman Chemical (Ann Arbor, MI).
Compound C and protein kinase A (PKA) inhibitor (rAMP) were
from Sigma Aldrich (St Louis, MO). EBM-2 medium was from
Lonza Clonetics (Walkersville, MD), and fetal bovine serum was
from Hyclone (Logan, UT). Dil-labeled acetylated low-density
lipoprotein (Dil-acLDL) was from Invitrogen (Carlsbad, CA) and
the Boyden chamber (8.0 mm) was from Becton Dickinson
(Franklin Lakes, NJ). Anti-p-AMPK-Thr172, anti-p-eNOS-Ser-
1177, anti-AMPK, and anti-eNOS antibodies were from Cell
Signaling Technology (Danvers, MA). The other primary
antibodies and all secondary antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA). Ulex europaeus agglutinin 1
(UEA-1) and all other reagents were of tissue-culture or molecular
biology grade and purchased from Sigma Aldrich.
BMC isolation, culture, and identification
BMCs were harvested by flushing through the femoral and
tibial bones and cultured with EBM-2 medium supplemented with
10% fetal bovine serum and cytokine cocktail. After culture for 7
to 10 days, clusters of BMC colonies grew at a high proliferative
rate into a monolayer with a spindle-shaped morphology. This cell
population appeared to be homogenous and maintained a similar
morphology. The population exhibited high levels of CD34, c-kit
and VEGF receptor 2 (VEGFR-2; Flk-1) and had high capacity for
taking up Dil-acLDL and binding to UEA-1. The methods and
results for BMC identification are in Figure S1. BMCs within
passages 5 were used in all experiments.
Cell migration and transwell assay
BMC migration was assessed by scratch-wound assay as
described [14]. A scratch in a cell monolayer was created, and the
resulting migration was captured at the beginning and 8 hr later.
The images were quantified for the rate of cell migration. The
transwell assay involved use of the Boyden chamber. In brief, 4610
4
cells/wellwassuspendedin200 ml.EBM-2mediumwasloadedinto
the upper chamber of a transwell cluster plate. A 0.4-ml EBM-2
medium was added to the lower chamber; 1 mM PGE2 or an equal
volume of DMSO was added to both chambers. After incubation
for 24 hr, cells that migrated onto the lower side of the membrane
were fixed with 2% paraformaldehyde and then stained with
Hoechst and DiIC18, a dye for plasma membrane staining. The
stained cells in each well were photographed and counted.
In situ immunofluorescence staining
Subconfluent BMCs grown on coverslips were treated as
indicated. The cells were fixed with 2% paraformaldehyde and
immunostained. The primary antibodies included goat anti-CD34,
rabbit anti-eNOS, rabbit anti-von Willebrand factor (vWF) or
mouse anti-VE-cadherin. The secondary antibodies were FITC-
conjugated anti-goat, FITC-conjugated anti-rabbit or TRITC-
conjugated anti-mouse antibodies. The nuclei were counterstained
Table 1. Primers used in this study.
MOUSE NM Position Product (bp) Forward (59 to 39) Reverse (59 to 39)
CD34 NM_001111059 +463 to +678 216 ACCACAGACTTCCCCAACTG CGGATTCCAGAGCATTTGAT
c-kit NM_001122733 +4580 to +4731 152 GGTATGTTGCCTTCACGGTT CATGACAACAGGACCTCCAA
CD31 NM_008816 +1070 to +1330 261 GTCATGGCCATGGTCGAGTA CTCCTCGGCATCTTGCTGAA
VWF NM_011708 +8682 to +8795 114 CCTGTGCAGCTACAGCGGATTC TTATTGTGGGCCCAGGAGGGCA
MMP2 NM_008610 +2144 to +2278 135 CTGATAACCTGGATGCCGTCGT CCAGCCAGTCTGATTTGA
MMP9 NM_013599 +1660 to +1887 228 TTCAAGGACGGTTGGTACT CTCTGGGCCTAGACCCAACTTA
CYP19a NM_007810 +115 to +262 138 CACATCCTCAATACCAGGTCC CAGAGATCCAGACTCGCATG
COX2 NM_011198 +1509 to +1702 194 AGAAGGAAATGGCTGCAGAA GCTCGGCTTCCAGTCTTGAG
EP1 NM_013641 +331 to +976 646 TTAACCTGAGCCTAGCGGATG CGCTGAGCGTATTGCACACTA
EP2 NM_008964 +1464 to +1589 126 ATGCTCCTGCTGCTTATCGT AGGGCCTCTTAGGCTACTGC
EP3 NM_011196 +914 to +1131 218 GGATCATGTGTGTGCTGTCC GCAGAACTTCCGAAGAAGGA
EP4 NM_008965 +82 to +305 224 GTTCCGAGACAGCAAAAGC CACCCCGAAGATGAACATCAC
b-Actin NM_007393 +809 to +948 140 GACGGCCAGGTCATCACTAT CGGATGTCAACGTCACACTT
doi:10.1371/journal.pone.0023554.t001
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microscope.
In vitro angiogenesis assay
In vitro angiogenesis of BMCs on Matrigel (Becton Dickinson)
was as we previously described [13].
In vivo vasculogenesis
The investigation conforms with the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication N0. 85–23, revised 1996).
The animal experimental protocol was approved by the Peking
University Institutional Animal Care and Use Committee
(LA2011-003). Male C57BL/6 mice (8 weeks old) were fed
standard laboratory chow and tap water ad libitum. The Matrigel
plug in vivo vasculogenesis assay was as described previously [13].
The BMCs isolated from wild-type mice were pretreated with
PGE2 for 24 hr, then 5610
5 cells were resuspended in 100 mL
Matrigel on ice. The mixture was implanted on the flanks of wild-
type or EP4
+/2 mice (n=6) by subcutaneous injection and left for
Figure 1. PGE2 induces the differentiation of BMCs. BMCs were pretreated with PGE2 (1 mM) for 24 hr. (A) Confocal microscopy of cells
immunostained with goat-anti-CD34 or rabbit-anti-endothelial nitric oxide synthase (eNOS) primary antibodies. (B) Confocal microscopy of treated
cells double-immunostained with rabbit anti-von Willebrand factor (vWF) and mouse anti-VE-cadherin primary antibodies. (C) BMCs were treated with
different doses of PGE2 as indicated; the mRNA levels of CD34, c-kit, CD31, vWF were detected by quantitative RT-PCR (qRT-PCR). Data are mean 6 SD
of the mRNA levels normalized to that of b-actin and expressed as fold of that of control (* p,0.05).
doi:10.1371/journal.pone.0023554.g001
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hematoxylin and eosin.
Adenovirus infection
Ad-AMPK-DN, a recombinant adenovirus expressing a dom-
inant-negative mutant of AMPK, was described previously [15].
Recombinant viruses were amplified, and the titers were
determined in HEK293 cells. Confluent BMCs were infected
with recombinant adenoviruses (50 multiplicity of infection) for
24 hr before further treatments. The parental adenoviral vector or
Ad-GFP was used as an infection control [13].
Quantitative real-time PCR and Western blot analysis
Total RNA was isolated from BMCs with use of TRIzol
reagent. The resulting cDNAs were used as templates for
quantitative RT-PCR with the EVA Green fluorescent DNA
stain. b-actin was used as an internal control. The nucleotide
sequences of the primers are in Table 1.
Western blot analysis followed standard protocols. The primary
antibodies were anti-p-AMPK-Thr172, anti-p-eNOS-Ser-1177,
anti-AMPK, anti-eNOS and b-actin.
Statistical analysis
The significance of variability was determined by ANOVA with
post-hoc comparison by Student’s t test for continuous variables
and by chi-square or Fisher’s exact test for nominal variables, as
appropriate. All results are mean 6 SD from at least 3
independent experiments. P,0.05 was considered statistically
significant.
Results
PGE2 induces the differentiation of BMCs to mature ECs
To detect the effect of PGE2 on the differentiation of BMCs, we
treated these cells with PGE2 and detected the differentiation
markers of ECs by immunostaining. Figure 1A shows that CD34
was downregulated and eNOS upregulated in PGE2-treated cells.
In addition, the expression of vWF and VE-cadherin, the markers
of mature ECs, was increased in cells treated with PGE2 (Fig. 1B).
Quantitative real-time PCR analysis revealed that the mRNA
levels of the progenitor cell markers CD34 and c-kit were
decreased and that of the EC markers CD31 and vWF increased
in BMCs treated with PGE2 in a dose-dependent manner,
especially at 1 mM (Fig. 1C).
PGE2 promotes the abilities of migration and tube
formation in BMCs
BMCs can be recruited to sites of neovascularization where they
differentiate into mature ECs in situ. We further investigated
whether PGE2 can induce BMC migration and increase tube
formation. Results from both scratch-wound and trans-well assays
showed that PGE2 increased the migration of BMCs (Fig. 2A,B).
This effect of PGE2 was not due to increased cell proliferation
because PGE2 did not change the cell proliferation index or cell
cycle (Fig.S2). We then detected the expression of matrix
metalloproteinases 2 and 9 (MMP2 and MMP9), which is
associated with migration ability. Real-time PCR results showed
that PGE2 upregulated the expression of MMP2 and MMP9
(Fig. 2C). Further, in vitro tube-formation assay revealed that PGE2
Figure 2. PGE2 enhanced the endothelial functions of BMCs. (A) BMCs were pretreated with PGE2 (1 mM) for 24 hr. Then, the confluent
monolayers of cells were scratch wounded, and the migration distance was observed after 8 hr. The black line indicates the original wound edge. The
mean distance of migration was quantified by measuring the average of 5 independent microscope fields for each of 3 independent experiments.
Magnification is6100. *P,0.05. (B) The cells migrating across the filters were stained. Magnification is6100. Representative results of 3 independent
experiments are shown. Migrated cells were quantified by the average of 4 randomly chosen high-power fields of 3 independent experiments, each
performed in duplicate. Data are mean6SD, *P,0.05. (C) BMCs were treated with PGE2 (1 mM) for 24 hr. mRNA levels of MMP2 and MMP9 were
examined by qRT-PCR. Data are mean 6 SD of the mRNA levels normalized to that of b-actin and expressed as fold of control (* p,0.05). (D) BMCs
were pretreated with PGE2 (1 mM) for 24 hr. Then, 1610
5 cells were plated onto Matrigel for 4 hr. Tube formation was determined by counting the
number of tubes in 5 randomly chosen low-power fields. Data are mean6SD from 3 independent experiments, each performed in triplicate
(*P,0.05).
doi:10.1371/journal.pone.0023554.g002
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Matrigel (Fig. 2D).
The differentiation effects of PGE2 on BMCs depended
on AMPK activation
We previously reported that AMPK plays a pivotal role in the
differentiation of BMCs [13]. We tested whether AMPK also has a
role in the differentiation of BMCs induced by PGE2. On
treatment with PGE2 from 15 min to 2 hr, the phosphorylation of
AMPKa at Thr172 peaked at 60 min; as well, the phosphoryla-
tion of eNOS at Ser1177, a target of activated AMPK, peaked at
60 min (Fig. 3A). The activation of AMPK blocked with
Compound C, a chemical activity inhibitor of AMPK, and DN-
AMPK, suppressed the increased mRNA levels of CD31, vWF,
MMP2 and MMP9 by PGE2 (Fig. 3B,C). As previously described,
PGE2 was able to activate PKA [16,17,18], but we found that
rAMP, a PKA inhibitor, did not alter the effect of PGE2 on the
differentiation and migration of BMCs (Fig. 4A) but did decrease
the expression of the positive controls CYP19 [19] and COX-2
[16,17,18], both reported to be upregulated by PGE2 through the
PKA-CREB pathway (Fig. 4B).
PGE2 effect was through its receptor EP4
PGE2 exerts its cellular effects through binding to its 4 distinct
transmembrane-specific G-protein-coupled receptors. We investi-
gated which receptor mediated the effect of PGE2 in BMC
Figure 3. PGE2 mediated the differentiation and migration of BMCs through AMPK activation. (A) BMCs were treated with PGE2 (1 mM)
for different times as indicated, and protein extracts were pooled and examined by western blot analysis. (B) BMCs were pretreated with Compound
C (10 mM) for 30 min, then cells were treated with PGE2 for 24 hr. (C) BMCs was pretreated without or with an adenovirus expressing a dominant-
negative mutant of AMPK (Ad-AMPK-DN, 50 multiplicities of infection) for 24 hr, then infected cells were treated with PGE2 for another 24 hr. (B, C)
Total mRNA was isolated and analyzed by qRT-PCR.
doi:10.1371/journal.pone.0023554.g003
PGE2 Promotes BMC Differentiation via AMPK
PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23554differentiation. We first detected the expression level of different
EPs in cultured BMCs and found that the expression of EP1 and
EP4 was higher than that of EP2 and 3, with the expression of EP4
the highest (Fig. S3). Then, we studied the role of different EPs in
mediating the activation of AMPK and tube formation. As shown
in Figure 5A, PGE1 alcohol, an EP4 agonist, but not the EP2
agonist butaprost or EP3/EP1 agonist sulprostone induced the
phosphorylation of AMPK and eNOS. Further, we found that the
phosphorylation of AMPK and eNOS induced by PGE2 was
inhibited by EP4 blocking peptide but not the other 3 blocking
peptides (Fig. 5B). The EP4 blocking peptide but not EP1–3
blocking peptides repressed the pro-angiogenic tube-formation
effect of PGE2 in BMCs (Fig. 5C). However, the EP4 agonist
could mimic the effect of PGE2 alcohol and simulate tube
formation (Fig. 5D). To further confirm the role of EP4 mediating
the effect of PGE2 in tube formation, BMCs were isolated from
EP4
+/2 mice and their wild-type littermates, EP4
+/+ mice. Tube
formation was lower in EP4
+/2 cells than in EP4
+/+ cells. The
response of PGE2 in EP4
+/2 cells was also largely diminished
(Fig. 6A).
PGE2 enhanced the vasculogenesis of BMCs in vivo
To relate our in vitro results with BMC function and angiogensis
in vivo, we observed capillary formation in Matrigel plugs
subcutaneously implanted in mice. BMCs from EP4
+/2 and
EP4
+/+ mice were pretreated with PGE2 and then resuspended
with Matrigel and injected subcutaneously into C57BL/6 mice.
After 7 days, Matrigel implants were removed, and hematoxylin
and eosin staining revealed more luminal structure in implants
with PGE2-treated EP4
+/+ BMCs than in untreated control or
PGE2-pretreated EP4
+/2 BMCs (Fig. 6B). To further characterize
the differentiation of these BMCs, VE-cadherin staining of
implants showed cells in the luminal structure positive for VE-
cadherin, for mature ECs (Fig. 6C). The number of luminal
structures was significantly higher in PGE2-treated EP4
+/+ cells
than in PGE2-treated EP4
+/2 cells (Fig. 6D). Furthermore, the
increasing luminal structures by PGE2 mainly from the injected
BMCs rather than cells from the host mice (Fig. S4). Therefore,
PGE2 induced the differentiation of BMCs via the EP4 receptor.
Discussion
PGE2 has been reported to modulate angiogenesis, the process
of new blood vessel formation, by promoting BMC proliferation,
migration and tube formation. We investigated the mechanism
underlying the stimulatory effects of PGE2 and its specific
receptors on angiogenesis and BMCs. We found that 1) PGE2
induced the differentiation and migration of BMCs, which was
followed by the upregulation of CD31 and vWF, markers of
differentiation to ECs, and the genes associated with migration,
MMP2 and MMP9; 2) the effects of differentiation of BMCs were
mediated by the activation of AMPK; and 3) the activation of
AMPK, the differentiation and migration, and the ability for tube
formation of BMCs induced by PGE2 were through its receptor
EP4.
EPCs, a minor subpopulation of peripheral blood mononuclear
cells first discovered by Asahara [1,2,20], are believed to be
derived from bone marrow progenitor cells, hematopoietic stem
cells and tissue resident stem cells [21]. A proteomic analysis
revealed that this population of cells might be contaminated by
platelet microparticles in cultures, which acquired ‘‘endothelial’’
characteristics (CD31, von Willebrand factor, lectin-binding), and
angiogenic properties [22]. CD34, CD31 [23] and FLK1 [24,25]
are still widely accepted as the identification markers of EPCs. The
BMCs used in our study were isolated from mice bone marrow
and had high capacity for uptake of Dil-acLDL and binding to
UEA-1, demonstrated by immunofluorescence staining. Flow
cytometry assay exhibited high levels of UEA (95.6%), FLK1
(63.04%), c-kit (47.67%) and CD31 (41.25%) in our isolated and
cultured BMCs. Many studies demonstrated that EPCs participate
Figure 4. Protein kinase A (PKA) has no effect on differentiation and migration of BMCs mediated by PGE2. BMCs was pretreated with
PKA inhibitor rAMP (PKAin; 10 mM) for 30 min, then cells were treated with PGE2 (1 mM) for 24 hr. Total mRNA was isolated and analyzed by real-time
RT-PCR for expression of CD31, vWF, MMP2, MMP9, CYP19 and COX2.
doi:10.1371/journal.pone.0023554.g004
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endothelial repair [27], limb ischemia [28], and wound healing
[29]. Circulating EPCs engraft into 15% to 29% of vessels of the
transplanted human heart [30,31]. EPCs contribute significantly
to angiogenic growth-factor–induced neovascularization and may
account for 26% of all ECs [32]. The population of cells in this
study should have similar characteristics of above mentioned
EPCs. During differentiation, BMCs gradually lose their original
hematopoietic markers such as c-Kit, CD34 and CD133 and
begin to express markers of mature ECs such as CD31, eNOS,
and vWF. However, markers for EPCs lack clear definition. In line
with the above evidence, we chose c-Kit and CD34 as markers of
Figure 5. PGE2 mediated vasculogenesis of BMCs via EP4 receptor. (A) BMCs was pretreated with or without butaprost (1 mM), sulprostone
(1 mM), PGE1 alcohol (1 mM) and (B) blocking peptides of EP1, EP2, EP3 and EP4 in for 15 min, then cells were treated with PGE2 (1 mM) for 60 min.
The total protein extracts were pooled, and the phosphorylation of AMPK and eNOS was examined by western blot analysis. BMCs were treated
without or with the blocking peptides and then treated with PGE2 in (C) and PGE1 alcohol in (D) for 24 hr for tube-formation assay as described in
Figure 2D. Data are means 6 SD from 3 independent experiments, each performed in triplicate (*P,0.05).
doi:10.1371/journal.pone.0023554.g005
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addition, we analyzed BMCs by FACS with UEA, FLK1 and c-
Kit for purity (Fig. S1). The mobilization and migration of BMCs,
regulated by many factors, can be a complicated process.
Upregulating and activating MMPs promote the mobilization of
BMCs from bone marrow [33,34] and their migration to the
ischemia region [35]. Indeed, we found upregulated MMP2 and
MMP9 accompanied by the migration of BMCs.
PGE2, a metabolite of arachidonic acid, was originally
discovered along with other prostanoids to act on blood vessels.
It is widely recognized as a mediator of inflammation, capable of
recruiting proinflammatory cells and causing pain. PGE2 has also
been considered a promoter of tumorigenesis because of its causal
association with tumor growth [36,37,38]. This action of PGE2
has been attributed to its ability to activate the angiogenic switch, a
process leading to angiogenesis [39]. PGE2 has been reported to
promote angiogenesis, probably by increasing proliferation,
migration and tube formation of BMCs. However, the mechanism
of the action is not yet fully elucidated. We previously reported
that activation of AMPK by VEGF and statins promoted the
differentiation of human cord-blood–derived EPCs into mature
ECs via an NO-dependent mechanism [13]. Here, we show that
Figure 6. The vasculogenesis of BMCs mediated by PGE2 is attenuated in EP4
+/2 mice. BMCs from EP4
+/2 mice or their wild-type
littermates were treated with PGE2 (1 mM) for 24 hr. (A) tube-formation assay was performed as described in Figure 2D. (B) and (C) cells mixed with
Matrigel were subcutaneously injected into C57BL/6 mice and kept for 7 days. (B) The cross sections of the implants underwent hematoxylin and
eosin (H&E) staining, and (C) immunohistochemical staining with anti-VE-cadherin (VE-Cad). Magnification 6400. The arrows indicate vessel-like
structures. All images are representative of implants from 6 different animals. (D) Microvessel density in Matrigel implants quantified by counting
luminal structures containing erythrocytes. Data are mean6SD microvessel density value determined from 3 different implants in 2 independent
experiments *P,0.05.
doi:10.1371/journal.pone.0023554.g006
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stream molecule eNOS. Blocking the activation of AMPK with
DN-AMPK and Compound C attenuated the effect of PGE2
promoting BMC differentiation into mature ECs (Fig. 3). This
finding is consistent with a previous report that the activation of
AMPK by PGE2 mediated COX2 expression in renal podocytes
[40]. However, PGE2 was also reported to negatively regulate
AMPK by a PKA-dependent mechanism in osteoblastic MG63
cells cultured in serum-deprived media [41], which suggests
different results for different conditions in different cell types.
PGE2 is known to activate the PKA-CREB pathway in many cells
[16,17,18]. In our study, PGE2 indeed caused PKA activation, as
evidenced by upregulation of CYP19 [19] and COX-2 [16,17,18],
both reported to be upregulated by PGE2 through PKA-CREB
pathway. rAMP, a PKA inhibitor, blocked the induction of COX-
2 and CYP19 by PGE2 but had little inhibitory effect on the
upregulation of genes related to differentiation and migration,
namely, CD31, vWF, MMP2 and MMP9 (Fig. 4). Hence, PGE2
may activate both PKA and AMPK pathways, but the action of
promoting the differentiation of BMCs is through activating
AMPK.
PGE2 has been shown to exert its cellular effects by binding to 4
distinct transmembrane receptors, namely, EP1–4. EP4 receptor
plays a critical role in PGE2-dependent in vitro migration of ECs,
and EP4 agonists induce increased vascularization in vivo [6]. EP4
also mediates the effect of PGE2 on angiogenesis in fracture
healing [42], ocular angiogenesis [38] and retinopathy. However,
Finetti et al. reported that PGE2 synergized with fibroblast growth
factor 2 to promote angiogenesis mainly through reinforcing
proliferation via the EP3 receptor in ECs [39]. EP3 was also found
to mediate the effect of PGE2 in tumors [43], chronic
inflammation [5], and wound healing [29]. EP2 was reported to
mediate pulmonary angiogenesis in a murine model of emphyse-
ma [44]. Our results showed that the EP4 blocking peptide
inhibited the pro-angiogenic effect of PGE2 and the EP4 agonist
could mimic the effect of PGE2. Importantly, the basic and PGE2-
promoted ability of tube formation of BMCs from EP4
+/2 cells
was lower than in cells from their wild-type littermates (Fig. 6).
Because the ductus arteriosus fails to close after birth in EP4
2/2
mice, thus resulting in neonatal death [45,46], we used the
heterozygous mice in this study. In line with the in vitro study,
BMCs from EP4
+/2 mice showed less tube formation than their
wild-type littermates in vivo. Thus, through promoting the
differentiation of BMCs, PGE2 reinforced the process of
angiogenesis by binding to its receptor EP4 in an AMPK-
dependent mechanism. This finding indicates that EP4 may be a
potential target for promoting the differentiation of BMCs to
mature ECs for clinical therapy in ischemic heart diseases.
In conclusion, PGE2 reinforced their neovascularization by
promoting the differentiation and migration of BMCs. This effect
was mediated by binding to the receptor of EP4 in an AMPK-
dependent manner. Thus, PGE2 upregulation may have clinical
value in ischemic heart disease.
Supporting Information
Figure S1 Identification of bone-marrow–derived cells
(BMCs). After 2 passages, (A) Confocal microscopy of BMCs
were treated with Dil-labeled acetylated low-density lipoprotein
(Dil-acLDL; red) for 4 hr at 37uC before binding of Ulex europeus
agglutinin (UEA; green) for 1 hr and stained with Hoechst (blue).
(B) BMCs were stained with UEA and antibodies against FITC-
conjugated anti-mouse c-kit, FITC-conjugated anti-mouse FLK1,
FITC-conjugated and FITC-labeled UEA and analyzed by FACS.
Data are representative of 3 separate experiments.
(TIF)
Figure S2 Prostoglandin E2 (PGE2) has no effect on the
proliferation of BMCs. BMCs were treated with PGE2 for
24 hr. (A) Cell cycle assay and (B) sulforhodamine B (SRB) assay
was performed as indicated. The results are representative of 3
separate experiments.
(TIF)
Figure S3 The relative expression level of different EPs
in BMCs. The BMCs were harvested by extracting total RNA for
quantitative RT-PCR with primers of different EPs.
(TIF)
Figure S4 PGE2 enhanced the vasculogenesis of BMCs
in vivo. After infection with GFP adenovirus, BMCs from
C57BL/6 mice were administered with PGE2 for 24 hr. Cells
mixed with Matrigel were subcutaneously injected into C57BL/6
mice and kept for 7 days, then implants were removed and GFP
positive cells in frozen sections were observed under fluorescence
microscopy.
(TIF)
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